BRAF and malignant colon neoplasm: In a panel of colon cancer cell lines available in our laboratory, we performed a complete mutational signature of EGFR downstream pathways and we selected four cell lines that are completely wild-type in RAS, BRAF and PIK3CA genes and that, therefore, are putatively sensitive to EGFR-targeted therapies.